OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
White
D L
DL
Saunders
V A
VA
Dang
P
P
Engler
J
J
Hughes
T P
TP
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D050811:Octamer Transcription Factor-1 / Q000235:genetics* / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D050811:Octamer Transcription Factor-1; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate